STAT-Diagnostica has successfully closed a Series B financing round of 22.1 million USD, aimed at advancing its innovative Near Patient Testing diagnostic system.

Information on the Target

STAT-Diagnostica, founded in 2010 and located in the Barcelona Science Park, specializes in developing innovative Near Patient Testing systems that streamline and accelerate the diagnosis of various medical conditions. The company's advanced in vitro diagnostic platform uniquely combines molecular and immunoassay techniques into a single, user-friendly device. Initial applications are focused on detecting infectious diseases, assessing antibiotic resistance, and identifying biomarkers in critically ill patients.

With the recent closing of a Series B financing round amounting to 22.1 million USD (17 million Euros), STAT-Diagnostica aims to complete the development of its diagnostic system and validate its first products clinically. The funding is instrumental in preparing for a European market launch scheduled for 2015, as stated by CEO and co-founder, Jordi Carrera, who highlights that the successful closing of this financing round underscores the potential of their technology in the rapidly evolving decentralized diagnostics sector.

Industry Overview in Spain

The Spanish diagnostic industry is experiencing significant growth, driven by advancements in technology and an increasing demand for rapid and accurate diagnostic solutions. This trend is particularly relevant in the era of personalized m